Who are albumin paclitaxel, cispatin, tislelizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/albumin-paclitaxel-cispatin-tislelizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

albumin paclitaxel, cispatin, tislelizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

albumin paclitaxel, cispatin, tislelizumab (albumin paclitaxel, cispatin, tislelizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Targeted chemotherapy, PD-1 inhibitor, platinum-based chemotherapy. Area: Oncology.

phase 3 Targeted chemotherapy, PD-1 inhibitor, platinum-based chemotherapy PD-1, tubulin, DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

albumin paclitaxel, cispatin, tislelizumab (albumin paclitaxel, cispatin, tislelizumab) — Lai-ping Zhong. Albumin paclitaxel is a targeted chemotherapy drug that delivers paclitaxel directly to tumors, while tislelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 pathway to enhance anti-tumor immune response, and cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
albumin paclitaxel, cispatin, tislelizumab TARGET	albumin paclitaxel, cispatin, tislelizumab	Lai-ping Zhong	phase 3	Targeted chemotherapy, PD-1 inhibitor, platinum-based chemotherapy	PD-1, tubulin, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Targeted chemotherapy, PD-1 inhibitor, platinum-based chemotherapy class)

Lai-ping Zhong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). albumin paclitaxel, cispatin, tislelizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/albumin-paclitaxel-cispatin-tislelizumab. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab